{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigc6qaamcis7vk77bkddzos6w224myk3y326sh4iapuynomxyoymq",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mojh5sh2jnz2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreig5xesxgmadgpmd4qqajh5texckvt7pul4nc5nryruhkrqqok555i"
    },
    "mimeType": "image/jpeg",
    "size": 879365
  },
  "path": "/news/2026-06-fap-radiopharmaceutical-therapy-broad-effectiveness.html",
  "publishedAt": "2026-06-17T18:20:05.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A novel radiopharmaceutical therapy approach that targets fibroblast activation protein (FAP)—which is highly expressed in many types of cancer—is safe and effective for patients, according to a new study published in the June issue of the Journal of Nuclear Medicine. In a study of nearly 90 patients with 21 different types of cancer, FAP-targeted radiopharmaceutical therapy achieved objective responses in approximately two-thirds of patients and disease control in more than 80%.",
  "title": "FAP-targeted radiopharmaceutical therapy shows broad effectiveness across multiple cancers"
}